Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma

NCT05418972 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT05418972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05418972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 14, 2023
Completion date
October 31, 2035
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii melanoma